CCND1 and benign prostatic hyperplasia: Based on this rationale, both miRNAs were selected for our study alongside β-catenin, Fzd8, β-catenin and cyclin D1, enabling an integrated assessment of transcript and protein expression patterns in BPH and prostate adenocarcinoma specimens.